<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): AUGUST 24, 1998
---------------
COPLEY PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation or organization)
0-20126 04-2514637
(Commission File Number) (IRS Employer Identification No.)
25 JOHN ROAD
CANTON, MASSACHUSETTS 02021
(Address of principal executive offices) (Zip Code)
(781) 821-6111
(Registrant's telephone number, including area code)
Page 1 of 3 Pages
<PAGE>
ITEM 5 OTHER EVENTS
On August 24, 1998, Copley Pharmaceutical, Inc. (NASDAQ: CPLY) announced the
appointment of Daniel L. Korpolinski as Copley's President and Chief Executive
Officer. Mr. Korpolinski also has been elected to the Company's Board of
Directors.
Prior to joining Copley Pharmaceutical, Inc., from 1991-1997 Mr. Korpolinski was
President and Chief Executive Officer of CoCensys, Inc., a biotech firm located
in Irvine, California. He came to CoCensys from Adria Laboratories of North
America where he had served as President from 1988-1991. Before joining Adria,
which developed, manufactured and marketed both proprietary and multisource
pharmaceutical products, Mr. Korpolinski was an employee of Upjohn
Pharmaceutical Company from 1964-1988. He ended his association with Upjohn
Pharmaceutical Company in Kalamazoo, Michigan where he held Executive Director
positions in both The Pharmaceutical and The Consumer Products Divisions.
Page 2 of 3 Pages
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
August 27, 1998 COPLEY PHARMACEUTICAL, INC.
/s/ Daniel M. P. Caron
----------------------
Daniel M. P. Caron
Vice President Finance, Chief Financial
Officer and Treasurer
(Principal Financial Officer)
Page 3 of 3 Pages
